Aquestive Q3 2026 slides show Anaphylm progress despite revenue miss
Aquestive Therapeutics reported Q3 2026 revenue of $7.5M, down 40.6% YoY and missing estimates. The company highlighted progress on Anaphylm, with FDA approval expected by March 2027. Cash reserves declined to $90.3M, but management expects year-end cash to exceed $70M. Shares rose 0.77% post-earnings.
How this was made
The 30-second read
Why it matters
The earnings miss highlights execution risk, while the FDA resubmission and PDUFA date provide a near‑term catalyst that could drive volatility.
Market read
Primary micro‑cap biotech news; relevance limited to specialty pharma investors.
What to watch
Cash runway remains strong above $70M and non‑dilutive financing reduces dilution risk.
Background
Aquestive Therapeutics is a micro‑cap biotech focused on novel epinephrine delivery. The company recently out‑licensed Libervant to Eton Pharmaceuticals for $10M upfront.
Ticker impact
Q3 2026 earnings miss (revenue down 40.6% YoY) and regulatory update on Anaphylm with a PDUFA target of March 16, 2027.
likely modest pressure as investors price in the revenue miss, tempered by regulatory progress support
Revenue fell sharply and missed consensus, driving short-term sell pressure; however, the resubmitted NDA and set PDUFA date are positive signals for future upside.
Market effects
Biotech sector may see modest uplift from a late-stage FDA filing, but overall impact limited to niche allergy therapeutics.
US biotech investors may adjust exposure; no broader regional effect.
Limited to investors tracking small-cap pharma pipelines.
Counterpoint
The regulatory milestone could outweigh the earnings miss, presenting a buying opportunity on dip.
Key entities
- ExecutiveDan Barber
CEO of Aquestive Therapeutics, quoted on regulatory progress.
- PartnerEton Pharmaceuticals
Recipient of out‑licensing deal for Libervant.


